Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03520075 · ClinicalTrials.gov registry record · Phase 1
Study of ASTX029 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 192
- Enrollment target
NCT03520075 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 192 participants.
The verdict
NCT03520075, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 192 participants
- Enrollment target
Study Summary
This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced solid malignancies who are not candidates for approved or available therapies.
Interventions
- DRUG ASTX029
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2018-05-07 |
| Est. Completion | 2025-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03520075
The ClinicalTrials.gov registry entry for NCT03520075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ASTX029 is the first listed.
NCT03520075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03520075 about?
NCT03520075 is a clinical study titled "Study of ASTX029 in Subjects With Advanced Solid Tumors". This study is a first-in-human, open-label, multicenter, Phase 1-2 study to assess the safety, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ASTX029 administered orally to participants with advanced solid malignancies who are not candidates for approved or available therap...
What is the current status of trial NCT03520075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 192 participants. The study started on 2018-05-07. Estimated completion is 2025-03-03.
What interventions are being tested in trial NCT03520075?
The interventions under investigation include: ASTX029 (DRUG).
Who is sponsoring clinical trial NCT03520075?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.